drugset / Trial / NCT02831686
A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma
Phase 1
Completed
18 enrolled
Memorial Sloan Kettering Cancer Center
Karyopharm Therapeutics Inc · collabMillennium Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety of a combination of study drugs called selinexor (KPT-330) and ixazomib (MLN9708) with a low dose of dexamethasone. This study tests different doses of the study drug, selinexor to see which dose is safer in people. Depending on which group (dose level) you are in, the dose of selinexor will vary, but the ixazomib and dexamethasone doses will be the same among the groups.
Timeline
- Start
- 2016-07
- Primary completion
- 2020-11-19
- Completion
- 2020-11-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selinexor | Other / unclassified | — | Oral |
| Background | Dexamethasone | Small molecule | — | Oral |
| Background | Ixazomib | Unknown | — | Oral |